Familial Hypercholesterolemia

In this Healio | Cardiology Today video exclusive, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It's Not Just a Phase.”

Population genomic screening for Lynch syndrome, familial hypercholesterolemia and hereditary breast and ovarian cancer may be cost-effective for adults aged younger than 40 years if the cost is “relatively low,” researchers reported.

About 75% of adults with heterozygous familial hypercholesterolemia do not meet guideline-recommended LDL treatment targets, whereas women with familial hypercholesterolemia are less likely than men to be appropriately treated, data show.

An Australian general practitioner-led screening and care program for heterozygous familial hypercholesterolemia was projected to be cost-effective with significant return on investment vs. standard care, researchers reported.

PCSK9 inhibition with alirocumab, on top of high-intensity statin therapy, resulted in significant coronary plaque regression among patients with familial hypercholesterolemia and no clinical atherosclerotic CVD, researchers reported.

Assessing odds for subclinical ASCVD by midlife based on maternal inheritance of FH.

Regeneron Pharmaceuticals announced the FDA has extended approval of evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous familial hypercholesterolemia in children aged 5 to 11 years.

A healthy lifestyle was associated with reduced risk for CVD among adults with familial hypercholesterolemia regardless of their familial hypercholesterolemia mutation status, researchers reported.

There is not yet enough evidence to adequately assess the benefit-harm balance of screening for lipid disorders in asymptomatic children and adolescents aged 20 years or younger, according to a statement from the U.S. Preventive Services Task Force.

Researchers in France observed that maternal inheritance of familial hypercholesterolemia was associated with greater odds of having subclinical coronary atherosclerosis compared with paternal inheritance of the gene mutation.